NeOnc Technologies Holdings, Inc. is trading 5.7% down at $4.89 today, pulling back from a sharp rally driven by positive regulatory news in the Middle East.
- The stock surged on June 16, 2026, after the company received Investigational New Drug (IND) authorization in Abu Dhabi for NEO212, its oral therapeutic candidate for brain tumors.
- Shares are currently giving back a portion of those gains as investors move to secure profits following the recent news-driven spike.